Objective: The aims of this study were to identify prognostic factors for overall survival (OS) in patients with small cell lung cancer (SCLC) and to construct a prognostic index on the basis of their expected OS. Long-term survivors were also given special attention. Methods: We retrospectively analyzed 295 patients diagnosed with SCLC from January 2002 to September 2007 at the Severance Hospital, Seoul, Republic of Korea. Patient history was reviewed regarding both clinical and tumor-related markers, and treatment-related factors were also evaluated. Results: There were 131 (44.4%) patients with limited disease (LD) and 164 (55.6%) with extensive disease (ED). Median follow-up lasted 9.4 months. Objective response to chemotherapy was 66.8%. The median survival time (MST) was 11.2 months in all patients, 20.4 months in LD patients, and 7.7 months in ED patients. The median progression-free survival was 9.4 months. Independent prognostic factors for overall survival (OS) were extent of disease, performance status, and CYFRA 21-1 level. We classified all patients into four groups based on the results of multivariate analysis using classification and regression tree analysis. Median survival times were 22.7, 13.7, 8.5, and 3.2 months, respectively. A total of 51 (17.3%) patients from the entire study population were evaluated for long-term survival, which was defined as survival >2 years. Their MST was 43.1 months, and extent of disease, performance status, and CYFRA 21-1 were independent prognostic factors for long-term survival. Conclusions: We confirmed the well-known prognosticators, disease extent and performance status, in our patients, but further identified CYFRA 21-1 as independent prognostic factor. A prognostic index was constructed to create four classifications of SCLC considering these variables.

Keywords:
CYFRA 21-1, Disease extent, Performance status, Prognostic factors, Small cell lung cancer, Survival
1.
Buccheri G, Ferrigno D: Prognostic factors of small cell lung cancer. Hematol Oncol Clin North Am 2004;18:445–460.
2.
Micke P, Faldum A, Metz T, Beeh KM, Bittinger F, Hengstler JG, Buhl R: Staging small cell lung cancer: Veterans Administration Lung Study Group versus International Association for the Study of Lung Cancer – what limits limited disease? Lung Cancer 2002;37:271–276.
3.
Bremnes RM, Sundstrom S, Aasebø U, Kaasa S, Hatlevoll R, Aamdal S: The value of prognostic factors in small cell lung cancer: results from a randomised multicenter study with minimum 5 year follow-up. Lung Cancer 2003;39:303–313.
4.
Sagman U, Maki E, Evans WK, Warr D, Shepherd FA, Sculier JP, Haddad R, Payne D, Pringle JF, Yeoh JL: Small-cell carcinoma of the lung: derivation of a prognostic staging system. J Clin Oncol 1991;9:1639–1649.
5.
Seifter EJ, Ihde DC: Therapy of small cell lung cancer: a perspective on two decades of clinical research. Semin Oncol 1988;15:278–299.
6.
Evans WK, Shepherd FA, Feld R, Osoba D, Dang P, Deboer G: VP-16 and cisplatin as first-line therapy for small-cell lung cancer. J Clin Oncol 1985;3:1471–1477.
7.
Murray N, Coy P, Pater JL, Hodson I, Arnold A, Zee BC, Payne D, Kostashuk EC, Evans WK, Dixon P: Importance of timing for thoracic irradiation in the combined modality treatment of limited-stage small-cell lung cancer. The National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 1993;11:336–344.
8.
Arriagada R, Le Chevalier T, Borie F, Rivière A, Chomy P, Monnet I, Tardivon A, Viader F, Tarayre M, Benhamou S: Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission. J Natl Cancer Instit 1995;87:183–190.
9.
Aupérin A, Arriagada R, Pignon JP, Le Péchoux C, Gregor A, Stephens RJ, Kristjansen PE, Johnson BE, Ueoka H, Wagner H, Aisner J: Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission. Prophylactic Cranial Irradiation Overview Collaborative Group. N Engl J Med 1999;341:476–484.
10.
Spiegelman D, Maurer LH, Ware JH, Perry MC, Chahinian AP, Comis R, Eaton W, Zimmer B, Green M: Prognostic factors in small-cell carcinoma of the lung: an analysis of 1,521 patients. J Clin Oncol 1989;7:344–354.
11.
Paesmans M, Sculier JP, Lecomte J, Thiriaux J, Libert P, Sergysels R, Bureau G, Dabouis G, Van Cutsem O, Mommen P, Ninane V, Klastersky J: Prognostic factors for patients with small cell lung carcinoma: analysis of a series of 763 patients included in 4 consecutive prospective trials with a minimum follow-up of 5 years. Cancer 2000;89:523–533.
12.
Stanley KE: Prognostic factors for survival in patients with inoperable lung cancer. J Natl Cancer Inst 1980;65:25–32.
13.
Osterlind K, Andersen PK: Prognostic factors in small cell lung cancer: multivariate model based on 778 patients treated with chemotherapy with or without irradiation. Cancer Res 1986;46:4189–4194.
14.
Gronowitz JS, Bergstrom R, Nou E, Pahlman S, Brodin O, Nilsson S, Kallander CF: Clinical and serologic markers of stage and prognosis in small cell lung cancer. A multivariate analysis. Cancer 1990;66:722–732.
15.
Albain KS, Crowley JJ, LeBlanc M, Livingston RB: Determinants of improved outcome in small-cell lung cancer: an analysis of the 2,580-patient Southwest Oncology Group data base. J Clin Oncol 1990;8:1563–1574.
16.
Videtic GM, Stitt LW, Dar AR, Kocha WI, Tomiak AT, Truong PT, Vincent MD, Yu EW: Continued cigarette smoking by patients receiving concurrent chemoradiotherapy for limited-stage small-cell lung cancer is associated with decreased survival. J Clin Oncol 2003;21:1544–1549.
17.
Allan SG, Stewart ME, Love S, Cornbleet MA, Smyth JF, Leonard RC: Prognosis at presentation of small cell carcinoma of the lung. Eur J Cancer 1990;26:703–705.
18.
Cerny T, Blair V, Anderson H, Bramwell V, Thatcher N: Pretreatment prognostic factors and scoring system in 407 small-cell lung cancer patients. Int J Cancer 1987;39:146–149.
19.
Cohen MH, Makuch R, Johnston-Early A, Ihde DC, Bunn PA Jr, Fossieck BE Jr, Minna JD: Laboratory parameters as an alternative to performance status in prognostic stratification of patients with small cell lung cancer. Cancer Treat Rep 1981;65:187–195.
20.
Jorgensen LG, Osterlind K, Genolla J, Gomm SA, Hernandez JR, Johnson PW, Lober J, Splinter TA, Szturmowicz M: Serum neuron-specific enolase (S-NSE) and the prognosis in small-cell lung cancer (SCLC): a combined multivariable analysis on data from nine centres. Br J Cancer 1996;74:463–467.
21.
Kawahara M, Fukuoka M, Saijo N, Nishiwaki Y, Ikegami H, Tamura T, Shimoyama M, Suemasu K, Furuse K: Prognostic factors and prognostic staging system for small cell lung cancer. Jpn J Clin Oncol 1997;27:158–165.
22.
Laberge F, Fritsche HA, Umsawasdi T, Carr DT, Welch S, Murphy WK, Chiuten DF, Dhingra HM, Farha P, Spitzer G, et al: Use of carcinoembryonic antigen in small cell lung cancer. Prognostic value and relation to the clinical course 1. Cancer 1987;59:2047–2052.
23.
Maestu I, Pastor M, Gomez-Codina J, Aparicio J, Oltra A, Herranz C, Montalar J, Munarriz B, Reynes G: Pretreatment prognostic factors for survival in small-cell lung cancer: a new prognostic index and validation of three known prognostic indices on 341 patients. Ann Oncol 1997;8:547–553.
24.
Pujol JL, Quantin X, Jacot W, Boher JM, Grenier J, Lamy PJ: Neuroendocrine and cytokeratin serum markers as prognostic determinants of small cell lung cancer. Lung Cancer 2003;39:131–138.
25.
Rawson NS, Peto J: An overview of prognostic factors in small cell lung cancer. A report from the Subcommittee for the Management of Lung Cancer of the United Kingdom Coordinating Committee on Cancer Research. Br J Cancer 1990;61:597–604.
26.
Sculier JP, Feld R, Evans WK, Shepherd FA, DeBoer G, Malkin DG, Malkin A: Carcinoembryonic antigen: a useful prognostic marker in small-cell lung cancer. J Clin Oncol 1985;3:1349–1354.
27.
Souhami RL, Earl HM, Ash CM, Spiro SG, Geddes D, Harper PG, Tobias JS: Prognostic factors in patients with small-cell lung cancer: preliminary results from a large randomised study. Antibiot Chemother 1988;41:77–82.
28.
Toh CK, Hee SW, Lim WT, Leong SS, Fong KW, Yap SP, Hsu AA, Eng P, Koong HN, Agasthian T, Tan EH: Survival of small-cell lung cancer and its determinants of outcome in Singapore. Ann Acad Med Singapore 2007;36:181–188.
29.
Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al: New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92:205–216.
30.
Christodolou C, Pavlidis N, Samantas E, Fountzilas G, Kouvatseas G, Pagdatoglou K, Palamidas F, Nikolaidis C, Angelidou M, Kalofonos HP, Kosmidis P, Skarlos DV: Prognostic factors in Greek patients with small cell lung cancer (SCLC). A Hellenic Cooperative Oncology Group study. Anticancer Res 2002;22:3749–3757.
31.
Lemon SC, Roy J, Clark MA, Friedmann PD, Rakowski W: Classification and regression tree analysis in public health: methodological review and comparison with logistic regression. Ann Behav Med 2003;26:172–181.
32.
Tamura M, Ueoka H, Kiura K, Tabata M, Shibayama T, Miyatake K, Gemba K, Hiraki S, Harada M: Prognostic factors of small-cell lung cancer in Okayama Lung Cancer Study Group Trials. Acta Med Okayama 1998;52:105–111.
33.
Yip D, Harper PG: Predictive and prognostic factors in small cell lung cancer: current status. Lung Cancer 2000;28:173–185.
34.
Song LH, Song XR, Zhang XQ, Qi JL, Li XJ, Tian H, Bu B: Prognostic factors in patients with small cell lung cancer (in Chinese). Zhonghua Zhong Liu Za Zhi 2004;26:413–416.
35.
Wolf T, Gillenwater HH: Treatment options for small cell lung cancer. Curr Oncol Rep 2004;6:268–271.
36.
Johnston-Early A, Cohen MH, Minna JD, Paxton LM, Fossieck BE, Ihde DC, Bunn PA, Matthews MJ, Makuch R: Smoking abstinence and small cell lung cancer survival. An association. JAMA 1980;244:2175–2179.
37.
Bergman B, Sorenson S: Smoking and effect of chemotherapy in small cell lung cancer. Eur Respir J 1988;1:932–937.
38.
de Wet M, Falkson G, Rapoport BL: Small cell lung cancer: analysis of factors influencing the response to treatment and survival. Oncology 1994;51:523–534.
39.
Molina R, Agusti C, Mañe JM, Filella X, Jo J, Joseph J, Giménez N, Estapé J, Ballesta AM: CYFRA 21-1 in lung cancer: comparison with CEA, CA 125, SCC and NSE serum levels. Int J Biol Markers 1994;9:96–101.
40.
Kinoshita M, Watanabe H, Ichiki M, Sumita S, Okubo Y, Matsunami M, Furuno H, Shiraishi T, Rikimaru T, Oizumi K: CYFRA 21-1 as a marker of lung cancer. Kurume Med J 1998;45:7–9.
41.
Lassen U, Osterlind K, Hansen M, Dombernowsky P, Bergman B, Hansen HH: Long-term survival in small-cell lung cancer: posttreatment characteristics in patients surviving 5 to 18+ years – an analysis of 1,714 consecutive patients. J Clin Oncol 1995;13:1215–1220.
© 2011 S. Karger AG, Basel
2011
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.